Scene And Heard At BIO – From The IN VIVO Blog
This article was originally published in The Pink Sheet Daily
Vaccine applications to FDA are booming; Vertex outgoing CEO Josh Boger on the vision of George Merck; Merck-Serono portfolio guru Vince Aurentz; a review of meeting swag, and more from Day 3 in Atlanta.
You may also be interested in...
Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar
Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.